Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. One system that has been especially useful in generating relevant and accurate biological data is the patient- derived xenograft (PDX) model for cancer studies.

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

APRIL 5, 2021

The Human Genome Project could not have succeeded without the use of bioinformatics. The minimum requirement to become a professional in the bioinformatics field includes having a bachelor’s and master’s degree in bioinformatics, computer engineering, computational biology, computer science, or related field.

Bioinformatics 59

Bioinformatics Engineer Scientist Genome 59

pharmaphorum

SEPTEMBER 16, 2022

Verily’s Immune Profiler platform is “a discovery engine consisting of proprietary immune profiling lab workflow, growing multi-omic database, and advanced analytical tools”. Verily’s Immune Profiler can, Kim asserted, “generate more than 8 million immune measures across 24 immune cell subsets”. What, then, is the solution?

Development 135

Development Research Drugs Clinical Trials 135

Drug Discovery World

FEBRUARY 6, 2024

Researchers from the University of Oslo, University of Chicago Pritzker School of Medicine, and Insilico Medicine used an AI target discovery engine to analyse transcriptomic data to identify dual targets for cancer and ageing 5. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

SEPTEMBER 6, 2022

The mysteries of cancer are starting to yield to the range of advanced therapies available and cell therapies – especially engineered cell therapies – are at the leading edge of that progress.” – Carlo Russo, CEO of Genenta.? . “In Research into genomic medicines is only at its infancy. Chris Nowers, CEO, ONK Therapeutics. . “

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

AUGUST 9, 2023

The technology and science that’s behind that uses the power of antibody engineering to produce antibody drug conjugates. Another area of research which is really exciting for the whole industry is genomics and genetically targeted medicines. That’s key for us.

Drugs 52

Drugs Antibody Big Data Medicine 52